Tango Therapeutics Announces First Patient Dosed in TNG462 Phase 1/2 Trial in Patients With MTAP-deleted Solid Tumors

Tango Therapeutics, a clinical-stage biotechnology company, has recently announced an important milestone in their research. The first patient has been dosed in the phase 1/2 trial of TNG462, a potential treatment for patients with MTAP-deleted solid tumors. This trial aims to assess the safety, pharmacokinetics, pharmacodynamics, and efficacy of TNG462. Notably, the drug has received Fast Track..